Tesamorelin: the monograph

Yes, for one use: Egrifta (tesamorelin) is FDA-approved to reduce excess abdominal fat in HIV-infected adults with lipodystrophy, approved November 10, 2010 under BLA 022505. No other use is approved. The label adds that long-term cardiovascular safety has not been established.

Yes, and the boundary matters as much as the yes. FDA approved Egrifta on November 10, 2010 (application 022505, later deemed a biologic license) for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. Two newer formulations, Egrifta SV (2019) and Egrifta WR (2025), carry the same single indication. The label's own Limitations of Use section states that long-term cardiovascular safety has not been established, that the drug is not indicated for weight loss management, and that prescribers should reconsider treatment in patients whose visceral fat does not shrink. Every other use you see marketed, general belly fat, body recomposition, anti-aging, liver fat, cognition, is off-label or research-stage, not an approved indication.

Not in the way it is marketed. The approval covers HIV-associated lipodystrophy only. In the one non-HIV randomized trial (60 obese adults with reduced GH secretion), visceral fat fell about 35 cm2 vs placebo but weight did not change: the label calls tesamorelin weight neutral.

Unpack the question into three honest answers. Approved use: no, the approval covers HIV-infected adults with lipodystrophy, full stop. General-population evidence: one randomized trial exists, 60 abdominally obese adults with reduced GH secretion treated for 12 months; visceral fat fell (treatment effect -35 cm2, P=0.003), triglycerides and carotid intima-media thickness improved, subcutaneous fat did not change, and no approval followed. Will you weigh less: the label states tesamorelin is not indicated for weight loss management because it has a weight neutral effect, and in the pivotal trials 26-week weight changes ran from -0.4 to +0.5 kg. Tesamorelin changes fat geometry (visceral fat measured by CT), not the number on the scale, and the visceral fat returns when injections stop. Anyone selling it as a belly-fat shot is selling against the label's own words.

The visceral fat comes back. In the trial extensions, patients switched to placebo regained VAT within 26 weeks (+22% and +16% from the switch point) while those continuing held their reduction; IGF-1 fell about 135 ng/mL. The extension authors wrote that effects do not last beyond treatment.

This is the best-documented fact about tesamorelin after the approval itself, because the trials were built to measure it: patients who completed 26 weeks of tesamorelin were re-randomized, some continuing, some blindly switched to placebo. The switchers regained visceral fat, +25 cm2 (+22%) in Study 1 and +24 cm2 (+16%) in Study 2 over the next 26 weeks, while continuers held at 0% and -5%. IGF-1 dropped back (-137 and -135 ng/mL). The extension publication states it plainly: upon discontinuation of tesamorelin, VAT reaccumulated, and effects do not last beyond the duration of treatment. The practical meaning: tesamorelin manages visceral fat the way antihypertensives manage blood pressure, only while taken. Anyone considering it should plan for that arithmetic, including the monitoring that continues alongside.

Same receptor, different molecules and fates. Tesamorelin is the full 44-amino-acid GHRH stabilized against DPP-4, with phase 3 trials and a current FDA approval. Sermorelin is the unstabilized 1-29 fragment; its product Geref is discontinued and only compounded versions exist today.

Both drive the pituitary's GHRH receptor, and the differences stack from there. Molecule: tesamorelin is the complete GHRH(1-44) sequence carrying a trans-3-hexenoyl group that resists DPP-4 degradation; sermorelin is the shortest fully active fragment, GHRH(1-29), unmodified, with an IV half-life around 4.3 minutes. Regulatory fate: tesamorelin ran two 26-week phase 3 trials in 806 patients and holds a current FDA approval with an active label; sermorelin's Geref was discontinued and no approved sermorelin product exists today, so everything sold is compounded. Evidence character: tesamorelin's trials measured a hard imaging endpoint (CT-measured visceral fat) plus lipids and safety at scale; the adult sermorelin literature measured hormone levels in small cohorts, and in the longest analog trial the early IGF-1 rise faded back toward baseline by week 16. Label infrastructure: tesamorelin has written contraindications and monitoring rules; sermorelin has none, because there is no label. Our sister site covers sermorelin in the same depth: sermorelinco.com.

Tesamorelin asks; HGH replaces. Tesamorelin stimulates your pituitary to release GH in its natural pulses and is approved for HIV-associated abdominal fat. Somatropin is the hormone itself, titrated against IGF-1 per its label. Neither is approved for anti-aging.

They sit at different points on the same axis. Tesamorelin is a releasing-factor analog: it signals pituitary somatotrophs, GH comes out in its natural pulsatile pattern, and the body's feedback loops stay in the circuit. Somatropin is recombinant GH itself, a direct replacement whose labels titrate dose against serum IGF-1 and direct dose cuts when IGF-1 exceeds the age-adjusted range. Indications barely overlap: tesamorelin is approved for excess abdominal fat in HIV-associated lipodystrophy; somatropin for GH deficiency and a list of pediatric conditions. On the aging question the record is symmetrical and negative: the systematic review of GH in healthy elderly adults found small body-composition changes, no weight change, and significantly more edema, arthralgia, carpal tunnel syndrome, and glucose problems, concluding GH cannot be recommended as anti-aging therapy, and its distribution for anti-aging is illegal in the US. Tesamorelin shares the class cautions (fluid retention, glucose, critical illness) and has no anti-aging approval either.

Two label-mandated tracks: IGF-1 monitored during therapy (consider stopping if persistently above 3 SDS; 36% of trial patients crossed that line by week 26) and glucose evaluated before starting and periodically during, because new diabetes was more frequent on drug (5% vs 1%).

The label writes the lab schedule for you. IGF-1: tesamorelin raises it substantially (pooled +108 ng/mL at 26 weeks), the consequences of prolonged elevation are unknown, and the label directs monitoring during therapy with discontinuation considered for persistent elevations above 3 standard deviation scores, particularly without robust efficacy. The trial numbers behind the rule: 47% of patients above 2 SDS and 36% above 3 SDS by week 26, appearing as early as week 13. Glucose: evaluate before starting and periodically during, because glucose intolerance can develop; HbA1c reached 6.5% or higher in 5% versus 1% on placebo (hazard ratio 3.3), and diabetic patients need retinopathy monitoring. Practical rhythm many clinicians derive: baseline IGF-1 and glucose, early recheck around 3 months (matching the week-13 signal), then periodic monitoring, but the prescriber sets the schedule, not this page.

Label contraindications: anyone with pituitary/hypothalamic axis disruption (surgery, tumor, irradiation, head trauma, hypopituitarism), active cancer, prior hypersensitivity to tesamorelin, or pregnancy. History of cancer requires case-by-case review; not for children; no data over 65.

Four groups are contraindicated outright. People with disruption of the hypothalamic-pituitary axis, including hypophysectomy, hypopituitarism, pituitary tumor or surgery, head irradiation, or head trauma, because the drug needs an intact axis to act on and the axis needs to be safe to stimulate. People with active malignancy: tesamorelin induces GH, a growth factor, and the label requires any preexisting malignancy to be inactive with treatment complete before starting, with discontinuation on any evidence of recurrence and a specific reminder that HIV-positive patients carry an elevated background malignancy risk. People with known hypersensitivity to tesamorelin or its excipients. And pregnancy, where the label reasons that visceral fat normally increases and modifying that offers no benefit with possible fetal harm (rat studies showed offspring hydrocephaly at 2 to 4 times clinical exposure). Beyond the contraindications: not indicated in children (growth acceleration risk with open epiphyses) and no information exists in patients over 65.

Most common (vs placebo over 26 weeks): injection site reactions 17% vs 6%, arthralgia 13% vs 11%, myalgia 6% vs 2%, peripheral edema 6% vs 2%, paresthesia 5% vs 2%. Watch-items: IGF-1 elevation, new glucose intolerance (5% vs 1% reached diabetic HbA1c), hypersensitivity (4%).

Two clusters dominate. The GH cluster, fluid retention showing up as arthralgia, peripheral edema, myalgia, paresthesia, and occasionally carpal tunnel syndrome, follows directly from induced growth hormone and is described by the label as transient or resolving on discontinuation. The injection cluster: site reactions (erythema, pruritus, pain, bruising) in 25% versus 14% on placebo across trials, reduced by rotating abdominal sites. The label's most-common list (over 5%): arthralgia, injection site erythema, injection site pruritus, pain in extremity, peripheral edema, myalgia. The monitoring-grade risks are covered in their own sections: IGF-1 elevation (47% above 2 SDS at 26 weeks), glucose intolerance and new diabetes (5% vs 1%, hazard ratio 3.3), hypersensitivity reactions in 4%, and the critical-illness caution. In the NEJM trial overall adverse events were similar between arms, though more tesamorelin patients withdrew for one. 740 patients received the drug across the trial program.

Subcutaneously into the abdomen once daily, rotating sites, avoiding scars, bruises, and the navel. Egrifta SV: mix the 2 mg vial with 0.5 mL sterile water (roll 30 seconds, never shake), inject 0.35 mL (1.4 mg) immediately, discard the rest. Never refrigerate or freeze the mixed solution.

The label choreography for Egrifta SV: reconstitute one 2 mg vial with 0.5 mL of the provided Sterile Water for Injection, giving 2 mg per 0.5 mL (4 mg/mL); mix by rolling the vial gently in your hands for 30 seconds, never shaking; inspect for particles and color (use only clear, colorless solution); inject 0.35 mL, the 1.4 mg dose, immediately; discard the unused remainder, and never freeze or refrigerate the reconstituted solution. Egrifta WR differs by design: its 11.6 mg vial is mixed once weekly with 1.3 mL of bacteriostatic water (8 mg/mL) and provides seven daily 0.16 mL doses before discard. Injection site is the abdomen only, rotated daily, avoiding scar tissue, bruises, and the navel; site rotation is also what the label recommends against the 25% injection-site-reaction rate. General subcutaneous technique guidance favors the shortest needles and systematic rotation so lipohypertrophy does not develop. Our reconstitution calculator does the arithmetic for any prescribed dose against the label constants.

In HIV: yes, in trials. The NIH-funded 12-month trial found liver fat fell 37% relative to baseline vs placebo, and 35% vs 4% reached normal liver fat. But tesamorelin is not approved for NAFLD anywhere, and no trial has tested it in NAFLD without HIV.

The liver data are the strongest off-indication evidence tesamorelin has, and they are still HIV-specific. Stanley 2014 (50 patients, 6 months) found visceral fat fell alongside a modest liver fat reduction (net -2.9% lipid-to-water, P=.003). The definitive test was Stanley 2019 (NCT02196831), an NIH-funded randomized trial in 61 people with HIV and NAFLD treated for 12 months: hepatic fat fraction fell by an absolute 4.1% (relative -37%, P=0.018), and 35% of tesamorelin patients versus 4% on placebo ended below the 5% threshold that defines hepatic steatosis, with no glucose or HbA1c penalty at 12 months. The honest boundaries: the trial authors themselves call for longer histology studies, tesamorelin holds no NAFLD indication in any population, and the general-population NAFLD trial has not been run. A recruiting exercise-adjunct trial in HIV shows where the research is going next.

No approved anti-aging use exists, and the strongest data are one 20-week trial: cognition scores improved in older adults (executive function P=.005) and brain GABA rose, but the authors called for longer trials and none has changed the label. GH-axis anti-aging therapy remains unproven.

There is a real signal and an honest ceiling. The signal: in the 20-week SMART trial (152 adults aged 55 to 87, including 66 with mild cognitive impairment), tesamorelin 1 mg nightly improved a cognitive composite (intent-to-treat P=.03, executive function P=.005), raised IGF-1 by 117% while staying in the physiologic range, and cut body fat 7.4%; a 30-person imaging substudy found increased brain GABA in all sampled regions. The ceiling: that is a single 20-week program whose authors state longer-duration trials are needed; no cognition or aging indication exists on any tesamorelin label; there is no information on use over age 65, the exact population anti-aging marketing targets; and the wider GH-axis record in healthy aging is cautionary, with the systematic review of GH in healthy elderly finding more edema, joint pain, carpal tunnel, and glucose problems for small body-composition gains and concluding it cannot be recommended as anti-aging therapy. Anti-aging tesamorelin is a hypothesis wearing a lab coat, not an established treatment.

Three realities: the approved products (Egrifta SV/WR) are prescription-only, and coverage typically tracks the approved HIV-lipodystrophy use; off-label prescriptions exist through clinics; and 'research' or compounded vials are not the FDA-approved product and carry no FDA review.

Access splits into three lanes worth naming precisely. Lane one, the label lane: Egrifta SV and Egrifta WR are prescription drugs, prescribed for the approved indication, reduction of excess abdominal fat in HIV-associated lipodystrophy; insurance coverage decisions typically ride on that indication, which is why coverage outside it is a case-by-case fight (we make no claims about prices or any specific plan). Lane two, off-label: US clinicians may legally prescribe an approved drug off-label, and longevity clinics do exactly that for body composition; the evidence behind that use is the thin slice described above, the label's weight-neutral language included, and the label-mandated IGF-1 and glucose monitoring does not disappear because the indication did. Lane three, the gray market: compounded or 'research' tesamorelin vials are not the approved product; FDA does not review compounded drugs for safety, effectiveness, or quality before marketing, and research-chemical vials receive no review at all. This site sells nothing and recommends no route; it documents what each route actually is.

All three were approved under BLA 022505: original Egrifta (2010, 1 mg vials, refrigerated), Egrifta SV (2019, 2 mg vial, room temperature, 1.4 mg dose), Egrifta WR (March 2025, 11.6 mg vial mixed weekly, 1.28 mg dose). SV and WR labels are current in 2026; the two are not substitutable.

The formulation history is a study in packaging the same exposure three ways. Original Egrifta (November 2010): 1 mg vials, two per 2 mg daily dose, mixed to 1 mg/mL, vials stored refrigerated. Egrifta SV (2019 supplements): one 2 mg vial mixed with 0.5 mL to 4 mg/mL; the dose became 1.4 mg in 0.35 mL because the new formulation delivers exposure similar to the old 2 mg; vials store at room temperature. Egrifta WR (approved March 25, 2025): an 11.6 mg vial mixed once weekly with 1.3 mL bacteriostatic water to 8 mg/mL, giving seven 1.28 mg (0.16 mL) daily doses, again exposure-matched to the original; room temperature storage, discard 7 days after mixing. Both SV and WR SPLs are current on DailyMed as of this writing (effective 2026-07-29), and the WR label states flatly that WR and SV are not substitutable, because doses, vial counts, diluents, and storage all differ. Which one a patient receives is a pharmacy and prescriber decision; which numbers apply at the syringe depends entirely on which box is in hand.